{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010275","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.681072+00:00","generated_at":"2026-05-21T12:02:29.948425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline","bullets":["Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.","Cash and equivalents $4.3M at March 31, 2025, after closing $5M public offering.","New U.S. patent for EVM401 Series (mescaline derivatives) and EB-003 IP expanded.","Signed two licensing agreements for cannabinoid-COX-2 conjugates with Restoration Biologics.","Targeting FDA IND submission for EB-003 by end of Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010275","json":"https://secwatch.observer/filing/0001641172-25-010275.json","markdown":"https://secwatch.observer/filing/0001641172-25-010275.md","text":"https://secwatch.observer/filing/0001641172-25-010275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/0001641172-25-010275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:02:29.948425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}